Naomi Kresge

Novo Nordisk A/S is asking for more time to answer questions from US Senator Bernie Sanders on the prices of Ozempic and Wegovy, the company's blockbuster drugs for diabetes and weight loss.

Novo Nordisk A/S , maker of hit drugs Ozempic and Wegovy, signed its third research deal with a biotech backed by Flagship Pioneering , agreeing to pay as much as $600 million to develop next-generation obesity treatments.

There is no escaping Ozempic and Wegovy. The diabetes and obesity drugs are a global phenomenon. They've won over the rich and famous, generated billions in sales and blown open a new market for weight loss drugs, which Goldman Sachs estimates will reach $100 billion a year by 2030.

(Bloomberg) -- Novo Nordisk A/S said an experimental hemophilia treatment taken as little as once a month reduced bleeding in a large clinical trial, potentially opening up a path to less frequent treatment for some patients.

Findings are from analysis of long-running Novo Nordisk trial Results could lead to wider prescribing of drug, doctors said

Novo Nordisk A/S’s blockbuster obesity drug Wegovy cut the risk of heart attacks and strokes irrespective of how much patients weighed, a study found, results that doctors said could drive more prescriptions for the medicine.

Novo Nordisk A/S is dipping a toe into research on whether weight-loss drugs can help people drink less alcohol, a field it's avoided so far as it concentrates on other conditions.

(Bloomberg) -- Senator Bernie Sanders is upping the pressure on Danish drugmaker Novo Nordisk A/S to lower the cost of its blockbuster weight-loss drug Wegovy, warning in a new report that if prices don't come down, the medication risks bankrupting the US health-care system.

Senator Bernie Sanders is upping the pressure on Danish drugmaker Novo Nordisk A/S to lower the cost of its blockbuster weight-loss drug Wegovy, warning